Referred to the House Committee on Energy and Commerce.
This bill requires that the U.S. retail list price for each prescription drug and biological product not exceed the annual average retail list price for that product across Canada, France, Germany, Italy, Japan, and the United Kingdom. Manufacturers must annually report list prices in the U.S. and those six countries to the HHS Secretary, who will calculate averages and issue implementing guidance and regulations.
Supporters emphasize lowering U.S. prices and transparency
Relative to its intended legislative type, this bill clearly establishes a substantive price-cap requirement and some basic administrative duties, but it is thin on the technical, fiscal, and procedural detail needed to implement and enforce a nationwide international-reference pricing regime.
This bill requires that the U.S. retail list price for each prescription drug and biological product not exceed the annual average retail list price for that product across Canada, France, Germany, Italy, Japan, and the United Kingdom.
Manufacturers must annually report list prices in the U.S. and those six countries to the HHS Secretary, who will calculate averages and issue implementing guidance and regulations.
Violations trigger a civil monetary penalty equal to ten times the per-unit difference between the U.S. list price and the calculated foreign average, charged per unit sold.
As‑introduced, a sweeping foreign‑reference price cap with steep penalties faces high political and implementation barriers; narrow odds absent major revisions.
Relative to its intended legislative type, this bill clearly establishes a substantive price-cap requirement and some basic administrative duties, but it is thin on the technical, fiscal, and procedural detail needed to implement and enforce a nationwide international-reference pricing regime.
Supporters emphasize lowering U.S. prices and transparency
These are examples from the analysis, not a ranked list of the most-affected groups.
Supporters emphasize lowering U.S. prices and transparency
Likely broadly supportive because the bill directly targets high U.S. drug prices by tying them to peer-country levels and increases price transparency.
Supporters would see it as holding manufacturers accountable and lowering out-of-pocket costs, while urging safeguards against access disruptions and stronger measures on net prices.
Cautiously favorable to the goal of lowering drug prices, but concerned about implementation details, legal vulnerability, and unintended consequences.
Would seek phased implementation, clearer definitions, and mechanisms to avoid harming innovation or supply.
Likely opposed as an inappropriate federal price-control mechanism that interferes with markets and risks harming innovation, supply, and investment in drug development.
Prefers market-based or targeted reforms instead of punitive penalties tied to foreign prices.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
As‑introduced, a sweeping foreign‑reference price cap with steep penalties faces high political and implementation barriers; narrow odds absent major revisions.
The bill has not accumulated any surfaced votes yet.
Supporters emphasize lowering U.S. prices and transparency
As‑introduced, a sweeping foreign‑reference price cap with steep penalties faces high political and implementation barriers; narrow odds ab…
Relative to its intended legislative type, this bill clearly establishes a substantive price-cap requirement and some basic administrative duties, but it is thin on the technical, fiscal, and procedural detail needed to…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.